

Rotblatt, Hart

From: transparency, state (Gen) <state.transparency@sandoz.com>
Sent: Wednesday, November 13, 2019 8:33 AM
To: AGO - High Cost Prescription Drugs
Subject: Notice of introduction of new high-cost prescription drug

Good morning,

Sandoz Inc. is submitting the below notice in response to Vermont statute 5.92 (Act 193). An act relating to prescription drug price transparency and cost containment § 4637 Notice of introduction of new high-cost prescription drugs.

NDC	Drug Product Description	Introduced to Market Date	WAC at Introduction
61314086601	ZIEXTENZO 6MG/0.6ML 1L/SY US	11/12/2019	\$3,925.53

Sandoz Inc. provides this report consistent with its understanding and interpretation of Vermont Act 193 (18 V.S.A. § 4637) and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of Vermont Act 193 (18 V.S.A. § 4637) as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights.

We believe that all information submitted by Sandoz Inc. to the Department of Vermont Health Access or to the Attorney General under Vt. Stat. tit. 18 §§ 4635 or 4637, including all information contained in this submission, is confidential and proprietary commercial or financial information not subject to disclosure, including under the Vermont Public Records Act (Subchapter 3 of Chapter 5 of the Vermont Statutes) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.'s related information herein to the maximum extent permitted by law. To the extent that any of this designated information is requested, whether under Vermont Public Records Act (Subchapter 3 of Chapter 5 of the Vermont Statutes) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure.

Sandoz Inc. (A Novartis Division)
100 College Road West
Princeton, NJ 08540
USA